OncologyOnline.net

Oncology Xagena

Xagena Mappa
Medical Meeting
Mediexplorer.it
Reumabase.it

Search results for "Urothelial carcinoma"

Neuroendocrine tumors ( NETs ) comprise a heterogeneous family of neoplasms with a wide and complex spectrum of clinical behavior. They originate in a great diversity of tissues and are characterized ...


A study has compared the incidence of vascular thromboembolic events ( VTEs ) in patients with metastatic or unresectable urothelial carcinoma ( UC ) who were treated with Gemcitabine and Carboplatin ...


Early results from a pivotal phase II study, IMvigor 210, of the investigational cancer immunotherapy Atezolizumab ( anti-PDL1; MPDL3280A ) in people with locally advanced or metastatic urothelial car ...


The outcomes and therapy of advanced urothelial carcinoma ( UC ) patients following discontinuation of PD-1/PD-L1 inhibitors are unclear. Researchers performed a retrospective analysis to examine ...


Trials of salvage therapy for advanced urothelial carcinoma have required prior Platinum-based therapy. This practice requires scrutiny since non-Platinum-based first-line therapy may be offered to Ci ...


Updated results from the pivotal phase II study, IMvigor 210, of the investigational cancer immunotherapy Atezolizumab ( MPDL3280A ) in people with locally advanced or metastatic urothelial carcinoma ...


Patients with metastatic urothelial carcinoma have few treatment options after failure of Platinum-based chemotherapy. In this trial, researchers have assessed treatment with Atezolizumab, an engineer ...


The results for Nivolumab ( Opdivo ) in the cohort of patients with metastatic urothelial cancer ( n=78 ), the most common type of bladder cancer, after Platinum-based therapy from CheckMate -032, a p ...


With few treatment options available to patients with advanced bladder cancer, investigators are looking for novel molecular targets. In a study published in The American Journal of Pathology, resea ...


Updated results from the phase 3 KEYNOTE-045 trial evaluating Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, in patients with locally advanced or metastatic urothelial carcinoma with disease progre ...


Nivolumab ( Opdivo ) has shown efficacy and acceptable safety in 2 open-label, multicenter studies ( CheckMate 032 and 275 ) and is approved for patients with metastatic urothelial carcinoma ( mUC ) ...


The results from an interim analysis of KEYNOTE-057, a phase 2 trial evaluating Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, for previously treated patients with high-risk non-muscle invasive bla ...


Activation of the PD-1 pathway has been implicated in resistance to BCG ( Bacillus Calmette–Guérin ) therapy. Pembrolizumab ( Keytruda ), a checkpoint inhibitor with significant activity in patients ...